Competitive landscape
Drugs aimed at the same indication, from approved to preclinical.
2 drugs for “Diffuse Large B-cell Lymphoma (DLBCL)”
Phase 3 2
- OdronextamabREGENERON PHARMACEUTICALS, INC.Diffuse Large B-cell Lymphoma (DLBCL)
- Rondecabtagene autoleucelLyell Immunopharma, Inc.Diffuse Large B Cell Lymphoma (DLBCL)
Drugs whose recorded indications name this term, by development stage. Indications come from registries and labels, so a drug can appear under related terms.